Tangential flow filtration is the workhorse of downstream bioprocessing — concentration, buffer exchange, and formulation in a single step. Membrane selection gets most of the attention. But for fragile biologics like viral vectors, cell therapies, and LNPs, the equipment architecture matters just as much.
Traditional TFF systems were designed for robust molecules — mAbs, industrial enzymes, simple proteins. Viral vectors have capsids that crack under shear. Enveloped viruses rupture from cavitation. LNPs disassemble under mechanical stress. Cell therapies require viability through every step. The equipment that works for mAbs may be destroying your advanced therapy product.
| Question to ask | Why it matters |
|---|---|
| What pump technology is inside? | Compression, suction, or impeller contact? Each creates different damage. Measured pulsation is the proof. |
| What is the actual TMP stability? | Not the control setpoint — the measured fluctuation over a 16-hour run. This determines flux consistency. |
| Does it scale without hardware changes? | Same pump, valves, and control from screening to clinical? Or does every scale require new equipment and revalidation? |
| What is the minimum working volume? | Can you run a 30 mL experiment without losing product to dead volume? |
| Does it require compressed air? | Pneumatic valves add infrastructure, contamination risk, and validation scope. |
| Is it membrane-agnostic? | Can you use cassettes and hollow fiber from any manufacturer? Or are you locked into one supplier's format? |
| What automation level? | Manual control, basic PID, or full ISA-88 batch recipes with 21 CFR Part 11 and ALCOA+ compliance? |
The question isn't "which membrane should I use?" It's "is this system designed for the biology I'm running?" The membrane is half the decision. The equipment architecture is the other half.
Processing fragile biologics? Let's talk about your TFF step.
Speak to an engineer